86606-04-4

Basic information

• Product Name: 2-Butenoic acid, 4-bromo-, 1,1-dimethylethyl ester, (2E)-
• CAS NO: 86606-04-4
• Molecular Formula: C8H13BrO2
• Molecular Weight: 221.094
• Mol File: 86606-04-4.mol

Chemical Properties

• CAS DataBase Reference: 2-Butenoic acid, 4-bromo-, 1,1-dimethylethyl ester, (2E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butenoic acid, 4-bromo-, 1,1-dimethylethyl ester, (2E)-(86606-04-4)
• EPA Substance Registry System: 2-Butenoic acid, 4-bromo-, 1,1-dimethylethyl ester, (2E)-(86606-04-4)

Safety Data

• Hazardous Substances Data: 86606-04-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Butenoic acid, 4-bromo-, 1,1-dimethylethyl ester, (2E)is used as a reagent in organic synthesis for the production of various chemical compounds. Its unique structure and properties make it a valuable component in the synthesis of a wide range of organic molecules.
Used in Fragrance and Flavor Production:
Due to its distinctive odor, 2-Butenoic acid, 4-bromo-, 1,1-dimethylethyl ester, (2E)is used in the production of various fragrances and flavors. It contributes to the creation of unique scents and tastes in a variety of consumer products, such as perfumes, colognes, and food items.
Used in Chemical Research:
2-Butenoic acid, 4-bromo-, 1,1-dimethylethyl ester, (2E)is also utilized in chemical research for studying various chemical reactions and processes. Its unique properties make it a valuable tool for understanding and advancing the field of chemistry.

Upstream product

• 13991-36-1 4-bromocrotonic acid 
• 115-11-7 isobutene 
• 79218-15-8 tert-butyl (E)-crotonate 

Downstream Products

• 845749-01-1 4-(2-formyl-6-methyl-phenoxy)-but-2-enoic acid tert-butyl ester 
• 845749-02-2 4-(2-formyl-4-methoxy-phenoxy)-but-2-enoic acid tert-butyl ester 
• 902154-51-2 γ-acetoxycrotonic acid tert-butyl ester 

Relevant articles and documents

SPIROCYCLIC TETRAHYDROQUINAZOLINES

Provided are compounds represented by Formula I, wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and (aa) are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula (I) are KRAS inhibitors and are thus useful to treat cancer and other diseases.

Spirocyclic tetrahydroquinazolines

The invention discloses spirocyclic tetrahydroquinazolines , and particularly provide compounds represented by Formula I shown in the specification, and pharmaceutically acceptable salts and solvates thereof. In the formula, R3, A, A1, A2, A3, E, E1, E2, L, Q, Z and a structure shown in the specification are as defined in the specification,. The compounds of formula I are KRAS inhibitors and are therefore useful in the treatment of cancer and other diseases.

NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES

A compound of formula (I) or a salt thereof wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono-or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected from a hydrogen atom, a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono-or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H- pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1- yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H- pyrazol-1-yl or 1H- pyrazol-1-yl.

Synthesis and determination of absolute configuration of a non-peptidic αvβ6 integrin antagonist for the treatment of idiopathic pulmonary fibrosis

A diastereoselective synthesis of (S)-3-(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid (1), a potential therapeutic agent for the treatment of Idiopathic Pulmonary Fibrosis, which is currently undergoing Phase I clinical trials is reported. The key steps in the synthesis involved alkylation of 2-methylnaphthyridine with (R)-N-Boc-3-(iodomethyl)-pyrrolidine, and an asymmetric Rh-catalysed addition of an arylboronic acid to a 4-(N-pyrrolidinyl)crotonate ester. The overall yield of the seven linear step synthesis was 8% and the product was obtained in >99.5% ee proceeding with 80% de. The absolute configuration of 1 was established by an alternative asymmetric synthesis involving alkylation of an arylacetic acid using Evans oxazolidinone chemistry, acylation using the resulting 2-arylsuccinic acid, and reduction. The absolute configuration of the benzylic asymmetric centre was established as (S).

Access to Polyfunctionalized Chiral Piperidines through Enantioselective Addition-Carbocyclization Cascade Reaction Catalyzed by a Rhodium(I)-Diene Complex

A new addition-carbocyclization cascade reaction initiated by arylboronic acids and catalyzed by a rhodium/chiral diene complex is described. Starting from N-bridged oxoenoate derivatives, highly functionalized piperidines bearing three contiguous stereogenic centers were obtained with excellent enantio- and diastereoselectivities.

NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS

A compound of formula (I) or a salt thereof (I) wherein R1 represents a hydrogen atom, a methyl group or a ethyl group R2 represents a hydrogen atom or a fluorine atom R3 represents a hydrogen atom, a methyl group or an ethyl group.

COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.

Asymmetric rhodium-catalysed addition of arylboronic acids to acyclic unsaturated esters containing a basic γ-amino group

Application of the Miyaura-Hayashi rhodium-catalysed addition of aryl boronic acids to acyclic unsaturated esters featuring basic centres to yield γ-amino butyric acids incorporating a substituted β-phenyl group is described. Unoptimised isolated yields and enantiomeric excesses vary from moderate to excellent, and the method tolerates a variety of substitution patterns and a range of functionality. Copyright

A peptide-catalyzed asymmetric Stetter reaction

Thiazolylalanine, in appropriately functionalized form, has been found to function as an enantioselective catalyst for an intramolecular Stetter reaction. Incorporation of the residue in a number of environments has resulted in a family of catalysts that

Enantioselective construction of all-carbon quaternary stereocenters using palladium-catalyzed asymmetric allylic alkylation of γ-acetoxy-α, β-unsaturated carbonyl compounds

We have successfully demonstrated that γ-acetoxy-α,β- unsaturated carbonyl compounds are useful starting materials for Pd-catalyzed asymmetric allylic alkylation to construct all-carbon quaternary stereocenters. With the use of 2-5 mol % of Pd catalyst an